All In Biotech

Drug Trial Radar · NCT03634852

A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery

A Two Different Chemoprophylaxis Approaches After Phacoemulsification Surgery in One Thousand Patients in Iraq :a Clinical Trial

Last checked: Nov 20, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,000

Actual

Start

Oct 1, 2016

Primary completion

Feb 1, 2018

Study completion Feb 1, 2018

Sponsor

Lead sponsor
Suzan A RattanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Al-Kindy College of Medicine
First posted
Aug 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 38 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Post cataract surgery bacterial endophthalmitis is a rare but the most devastating complication with a poor visual outcome. The preferred pattern of chemoprophylaxis varied world widely. The use of preoperative povidone iodine is universal. Most European surgeons prefer the use of Intracameral (IC) antibiotics whereas topical fluoroquinolone that prescribed perioperatively is the most common pattern in the United state(US). The current study aimed to evaluate the effectivity and safety of a combination of diluted IC Moxifloxacin and subconjunctival (SC) Triamcinolone acetonide as prophylaxis of bacterial endophthalmitis and postoperative inflammation in five hundred phacoemulsification surgeries and compare its results with the same number of patients treated by topical Moxifloxacin hydrochloride and Dexamethasone eye drops when given four times a day for 1month postoperatively.

Conditions

  • Endophthalmitis Postoperative

Interventions

  • Moxifloxacin hydrochloride 0.5% eye dropsDrug

    were prescribed four times a day for 1-month postoperatively

  • Dexamethasone 0.1% eye dropsDrug

    were prescribed four times a day for 1-month postoperatively

  • Intracameral Moxifloxacin 0.1%Drug

    Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq. Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient.

  • Subconjunctival Triamcinolone acetonide 4 mg /0.4 mlDrug

    Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country. The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Bacterial endophthalmitis in 1000 phacoemulsification surgeriesTime frame: The duration of follow up for each patient was a 3 months postoperatively.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.